Study identifier:D8450C00005
ClinicalTrials.gov identifier:NCT06194825
EudraCT identifier:N/A
CTIS identifier:N/A
A Phase 3, Randomized Study, With Initial 24-week, Double-Blind and Placebo-Controlled Treatment Phase, Followed by An 80-week Open-label Extension Treatment Phase to Evaluate the Effect of Eplontersen on the Transthyretin Reduction and Long-Term Safety in Chinese Participants With Transthyretin Amyloid Cardiomyopathy (EPIC-ATTR)
Transthyretin Amyloid Cardiomyopathy
Phase 3
No
Eplontersen, Placebo
All
60
Interventional
20 Years - 90 Years
Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment
Verified 01 Jun 2024 by AstraZeneca
AstraZeneca
-
No locations available
Arms | Assigned Interventions |
---|---|
Experimental: Eplontersen Eplontersen by subcutaneous injection once every 4 weeks | Drug: Eplontersen Eplontersen by subcutaneous injection |
Placebo Comparator: placebo Eplontersen-matching placebo by subcutaneous injection once every 4 weeks | Drug: Placebo Eplontersen-matching placebo by subcutaneous injection |